Apoquel

Argus’ Jacob Kilstein believes Zoetis Inc (NYSE: ZTS) has been benefiting from a “lack of generic competition in the animal drug space.” Kilstein maintains a Buy rating on the company, while raising the price target from $54 to $58. Benefiting From Animal Drug Space The analyst...

Zoetis Inc (NYSE: ZTS) has been meaningfully outperforming specialty pharma peers year-to-date. Citi’s Liav Abraham downgraded the company from Buy to Neutral, while raising the price target from $46 to $50. Upside Unlikely While maintaining a constructive stance on Zoetis’ fundamentals...